|
1
|
Sanyal AJ, Yoon SK and Lencioni R: The
etiology of hepatocellular carcinoma and consequences for
treatment. Oncologist. 15 Suppl 4:S14–S22. 2010. View Article : Google Scholar
|
|
2
|
Pievsky D and Pyrsopoulos N: Profile of
tivantinib and its potential in the treatment of hepatocellular
carcinoma: The evidence to date. J Hepatocell Carcinoma. 3:69–76.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Enguita-Germán M and Fortes P: Targeting
the insulin-like growth factor pathway in hepatocellular carcinoma.
World J Hepatol. 6:716–737. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feitelson MA, Arzumanyan A, Kulathinal RJ,
Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML,
Nawroth R, Sanchez-Garcia I, Sharma D, et al: Sustained
proliferation in cancer: Mechanisms and novel therapeutic targets.
Semin Cancer Biol. 35:S25–S54. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Derenzini M, Trerè D, Pession A, Govoni M,
Sirri V and Chieco P: Nucleolar size indicates the rapidity of cell
proliferation in cancer tissues. J Pathol. 191:181–186. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
López-Sáez JF, de la Torre C, Pincheira J
and Giménez-Martín G: Cell proliferation and cancer. Histol
Histopathol. 13:1197–1214. 1998.PubMed/NCBI
|
|
7
|
Glimcher LH: XBP1: The last two decades.
Ann Rheum Dis. 69 Suppl 1:i67–i71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marumoto Y, Terai S, Urata Y, Matsumoto T,
Mizunaga Y, Yamamoto N, Jin H, Fujisawa K, Murata T, Shinoda K, et
al: Continuous high expression of XBP1 and GRP78 is important for
the survival of bone marrow cells in CCl4-treated cirrhotic liver.
Biochem Biophys Res Commun. 367:546–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen X, Iliopoulos D, Zhang Q, Tang Q,
Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, et
al: XBP1 promotes triple-negative breast cancer by controlling the
HIF1α pathway. Nature. 508:103–107. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ming J, Ruan S, Wang M, Ye D, Fan N, Meng
Q, Tian B and Huang T: A novel chemical, STF-083010, reverses
tamoxifen-related drug resistance in breast cancer by inhibiting
IRE1/XBP1. Oncotarget. 6:40692–40703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu Y, Hou X, Liu M, Yang Z, Bi Y, Zou H,
Wu J, Che H, Li C, Wang X, et al: XBP1 silencing decreases glioma
cell viability and glycolysis possibly by inhibiting HK2
expression. J Neurooncol. 126:455–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chae U, Park SJ, Kim B, Wei S, Min JS, Lee
JH, Park SH, Lee AH, Lu KP, Lee DS and Min SH: Critical role of
XBP1 in cancer signalling is regulated by PIN1. Biochem J.
473:2603–2610. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun H, Lin DC, Guo X, Masouleh Kharabi B,
Gery S, Cao Q, Alkan S, Ikezoe T, Akiba C, Paquette R, et al:
Inhibition of IRE1α-driven pro-survival pathways is a promising
therapeutic application in acute myeloid leukemia. Oncotarget.
7:18736–18749. 2016.PubMed/NCBI
|
|
14
|
Diehl JA, Fuchs SY and Koumenis C: The
cell biology of the unfolded protein response. Gastroenterology.
14138(41–41): e1–2. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang D and Richardson DR: Endoplasmic
reticulum protein 29 (ERp29): An emerging role in cancer. Int J
Biochem Cell Biol. 43:33–36. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Greene CM, Varley RB and Lawless MW:
MicroRNAs and liver cancer associated with iron overload:
Therapeutic targets unravelled. World J Gastroenterol.
19:5212–5226. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xiao F, Zhang W, Chen L, Chen F, Xie H,
Xing C, Yu X, Ding S, Chen K, Guo H, et al: MicroRNA-503 inhibits
the G1/S transition by downregulating cyclin D3 and E2F3 in
hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Duan Q, Wang X, Gong W, Ni L, Chen C, He
X, Chen F, Yang L, Wang P and Wang DW: ER stress negatively
modulates the expression of the miR-199a/214 cluster to regulates
tumor survival and progression in human hepatocellular cancer. PLoS
One. 7:e315182012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yu MC, Yuan JM and Lu SC: Alcohol,
cofactors and the genetics of hepatocellular carcinoma. J
Gastroenterol Hepatol. 23 suppl 1:S92–S97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Poon D, Anderson BO, Chen LT, Tanaka K,
Lau WY, Van Cutsem E, Singh H, Chow WC, Ooi LL, Chow P, et al:
Management of hepatocellular carcinoma in Asia: Consensus statement
from the Asian Oncology Summit 2009. Lancet Oncol. 10:1111–1118.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Monga SP: Role of Wnt/β-catenin signaling
in liver metabolism and cancer. Int J Biochem Cell Biol.
43:1021–1029. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bisteau X, Caldez MJ and Kaldis P: The
complex relationship between liver cancer and the cell cycle: A
story of multiple regulations. Cancers (Basel). 6:79–111. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Breuhahn K, Longerich T and Schirmacher P:
Dysregulation of growth factor signaling in human hepatocellular
carcinoma. Oncogene. 25:3787–3800. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hasegawa D, Calvo V, Avivar-Valderas A,
Lade A, Chou HI, Lee YA, Farias EF, Aguirre-Ghiso JA and Friedman
SL: Epithelial Xbp1 is required for cellular proliferation and
differentiation during mammary glanddevelopment. Mol Cell Biol.
35:1543–1556. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xia T, Tong S, Fan K, Zhai W, Fang B, Wang
SH and Wang JJ: XBP1 induces MMP-9 expression to promote
proliferation and invasion in human esophagealsquamous cell
carcinoma. Am J Cancer Res. 6:2031–2040. 2016.PubMed/NCBI
|
|
29
|
Yang J, Cheng D, Zhou S, Zhu B, Hu T and
Yang Q: Overexpression of X-Box binding protein 1 (XBP1) correlates
to poor prognosis and up-regulation of PI3K/mTOR in human
osteosarcoma. Int J Mol Sci. 16:28635–28646. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li CW, Chang PY and Chen BS: Investigating
the mechanism of hepatocellular carcinoma progression by
constructing geneticand epigenetic networks using NGS data
identification and big database mining method. Oncotarget.
7:79453–79473. 2016.PubMed/NCBI
|
|
31
|
El-Abd NE, Fawzy NA, El-Sheikh SM and
Soliman ME: Circulating miRNA-122, miRNA-199a, and miRNA-16 as
biomarkers for early detection of hepatocellular carcinoma in
egyptian patients with chronic hepatitis c virus infection. Mol
Diagn Ther. 19:213–220. 2015. View Article : Google Scholar : PubMed/NCBI
|
